CCR5 and RANTES gene expression for interaction of peripheral blood mononuclear leukocytes in vitro and composite materials in patients with osteogenesis imperfecta

In our opinion, determination of the levels of RANTES-CCR5 system expression on blood mononuclear leucocytes in vitro can be used for individual evaluation of the perspective of implant material as inflammatory/osteoinductive reaction trigger in patients with osteogenesis imperfecta (OI). Besides, RANTES gene expression on blood mononuclear leucocytes may be effective in the development of the methods to predict the degree of inflammatory (osteolytic) response, while CCR5 gene expression - in the development of the methods to predict the process of reparative bone tissue remodeling in response to using different implants.